Early changes in biochemical markers of bone turnover predict the long- term response to alendronate therapy in representative elderly women: A randomized clinical trial

Journal of Bone and Mineral Research

Volumn 13, Issue 9, 1998, Pages 1431-1438

  Greenspan, Susan L ^a,b   Parker, Robert A ^b   Ferguson, Lauren ^a   Rosen, Harold N ^a,b   Maitland Ramsey, Lauri ^a   Karpf, David B ^c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Roche Global Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; CALCIUM; PLACEBO; VITAMIN D;

AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; HIP; HUMAN; MAJOR CLINICAL STUDY; OSTEOLYSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; RANDOMIZED CONTROLLED TRIAL; SPINE; TREATMENT OUTCOME;

AGED; ALENDRONATE; ALKALINE PHOSPHATASE; AMINO ACIDS; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; CALCIUM, DIETARY; COLLAGEN; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; FEMALE; FEMUR; HUMANS; OSTEOCALCIN; PEPTIDES; RADIUS; SPINE; VITAMIN D;

EID: 0031689775     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1998.13.9.1431     Document Type: Article

References (29)

1. Melton LJ III, Chrischilles EA, Cooper C, Lane AW, Riggs BL 1992 How many women have osteoporosis? J Bone Miner Res 7:1005-1010.
2. Chrischilles EA, Butler CD, Davis CS, Wallace RB 1991 A model of lifetime osteoporosis impact. Arch Intern Med 151: 2026-2032.
3. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, Judd HL, Caplan RH, Riggs BL 1992 Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 117:1-9.
4. The Writing Group for the PEPI Trial 1996 Effects of hormone therapy on bone mineral density. JAMA 276:1389-1396.
5. Lindsay R, Tohme JF 1990 Estrogen treatment of patients with osteoporosis. Obstet Gynecol 76:290-295.
6. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE, Fracture Intervention Trial Research Group 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541.
7. Overgaard K, Hansen MA, Jensen SB, Christiansen C 1992 Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study. BMJ 305:556-561.
8. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC II, Lombardi A, Shah R, Hirsch LJ, Karpf DB 1995 Effect of treatment with oral alendronate on bone mineral density and fracture incidence in postmenopausal osteoporosis. N Engl J Med 333: 1437-1443.
9. Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC Jr, Adami S, Harris ST, Santora IIAC, Hirsch LJ, Oppenheimer L, Thompson D 1997 for the Alendronate Osteoporosis Treatment Study Groups Prevention of nonvertebral fractures by alendronate: A meta-analysis. JAMA 277:1159-1164.
10. Dresner-Pollak R, Parker RA, Poku M, Thompson J, Seibel MJ, Greenspan SL 1996 Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif Tissue Int 59:328-333.
11. Garnero P, Hausherr E, Chapuy M-C, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD 1996 Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective Study. J Bone Miner Res 11:1531-1538.
12. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700.
13. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM 1993 Bone density at various sites for prediction of hip fractures. Lancet 341:72-75.
14. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Porras AG 1993 Clinical pharmacology of alendronate sodium. Osteoporos Int 3 (Suppl 3):S13-S16.
15. Dawson-Hughes B, Jacques P, Shipp C 1987 Dietary calcium intake and bone loss from the spine in healthy postmenopausal women. Am J Clin Nutr 46:685-687.
16. Greenspan SL, Maitland LA, Myers ER, Krasnow MB, Kido TH 1994 Femoral bone loss progresses with age: A longitudinal study in women over age 65. J Bone Miner Res 9:1959-1965.
17. Greenspan SL, Maitland-Ramsey L, Myers E 1996 Classification of osteoporosis in the elderly is dependent on site-specific analysis. Calcif Tissue Int 58:409-414.
18. Hanson DA, Weis ME, Bollen A-M, Maslan SL, Singer FR, Eyre DR 1992 A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7:1251-1258.
19. Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ 1994 Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 9:1643-1649.
20. Gomez BJ, Ardakani S, Ju J, Jenkins D, Cerelli MJ, Daniloff GY, Kung FT 1995 Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 41:1560-1566.
21. Bone HG, Downs RW Jr, Tucci JR, Harris ST, Weinstein RS, Licata AA, McClung MR, Kimmel DB, Gcrtz BJ, Hale E, Polvino WJ 1997 for the Alendronate Elderly Osteoporosis Study Centers dose-response relationships for alendronate treatment in osteoporotic elderly women. J Clin Endocrinol Metab 82:265-274.
22. Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S 1994 Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res 9:1833-1837.
23. Harris ST, Gertz BJ, Genant HK, Eyre DR, Survill TT, Ventura JN, DeBrock J, Ricerca E, Chesnut CH III 1993 The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 76:1399-1406.
24. Bauer DC, Black DM, Ott SM, Santora A, Thompson D, Ennis M, Cummings SR 1997 Biochemical markers predict spine but not hip BMD response to alendronate: The fracture intervention trial (FIT). J Bone Miner Res 12 (Suppl):S150 (abstract).
25. Greenspan SL, Myers ER, Maitland LA, Resnick NM, Hayes WC 1994 Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly. JAMA 271:128-133.
26. Hui SL, Slemenda CW, Johnston CC Jr 1989 Baseline measurement of bone mass predicts fractures in white women. Ann Intern Med 111:355-361.
27. Rosen HN, Dresner-Pollak R, Moses AC, Rosenblatt M, Zeind AJ, Clemens JD, Greenspan SL 1994 Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int 54:26-29.
28. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD 1995 Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 10:641-649.
29. Garnero P, Delmas PD 1993 Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 77:1046-1053.